Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been clinically diagnosed with hepatocellular carcinoma (a type of liver cancer)
- People for whom laparoscopic hepatectomy (keyhole surgery to remove part of the liver) has been chosen as the surgical approach, and who agree to take part
Who may not be able to join:
- People under 18 years of age
- People who are pregnant
- People who decline to receive blood product transfusions if needed
- People with active heart problems, such as unstable chest pain, poorly controlled heart failure, serious irregular heartbeat, severe heart valve disease, or a history of congestive heart failure
- People with a significant history of stroke or other cerebrovascular (brain blood vessel) disease
- People with lung conditions that restrict or block normal breathing
- People with high blood pressure that is not well controlled
- People with reduced kidney function, specifically a filtration rate below 60 mL/min (confirm with trial site)
- People with a low haemoglobin level (below 100 g/L), which may indicate anaemia
- People with abnormal blood clotting results, including a clotting measure (INR) above 1.5 when not on warfarin, and/or a low platelet count below 100 ×10⁹/L
- People with signs of a liver processing disorder, specifically elevated bilirubin above 35 mmol/L (confirm with trial site)
- People with an active infection at the time of the trial
- People who have donated their own blood before the operation (preoperative autologous blood donation)
- People who have received the drug erythropoietin at any point during their hospital stay for this procedure
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shijiang Liu, MD, The First Affiliated Hospital with Nanjing Medical University
Phone: +862568303569
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The proportion of allogeneic red blood cell products transfusion
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.